$7.80
3.58% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US98986M1036
Symbol
ZYXI

Zynex, Inc. Stock price

$7.80
-0.15 1.89% 1M
-3.21 29.16% 6M
-3.09 28.37% YTD
-1.02 11.56% 1Y
-5.39 40.88% 3Y
-0.53 6.41% 5Y
+7.64 4,846.10% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.29 3.58%
ISIN
US98986M1036
Symbol
ZYXI
Sector

Key metrics

Market capitalization $248.39m
Enterprise Value $285.44m
P/E (TTM) P/E ratio 52.70
EV/FCF (TTM) EV/FCF 18.30
EV/Sales (TTM) EV/Sales 1.47
P/S ratio (TTM) P/S ratio 1.28
P/B ratio (TTM) P/B ratio 6.94
Revenue growth (TTM) Revenue growth 4.21%
Revenue (TTM) Revenue $193.66m
EBIT (operating result TTM) EBIT $8.85m
Free Cash Flow (TTM) Free Cash Flow $15.60m
Cash position $37.63m
EPS (TTM) EPS $0.15
P/E forward 40.45
P/S forward 1.29
EV/Sales forward 1.47
Short interest 31.79%
Show more

Is Zynex, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Zynex, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Zynex, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Zynex, Inc. forecast:

Buy
100%

Financial data from Zynex, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
194 194
4% 4%
100%
- Direct Costs 40 40
6% 6%
21%
154 154
4% 4%
79%
- Selling and Administrative Expenses 141 141
12% 12%
73%
- Research and Development Expense - -
-
-
13 13
42% 42%
7%
- Depreciation and Amortization 4.53 4.53
2% 2%
2%
EBIT (Operating Income) EBIT 8.85 8.85
52% 52%
5%
Net Profit 4.82 4.82
70% 70%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Zynex, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Zynex, Inc. Stock News

Neutral
Seeking Alpha
22 days ago
Zynex, Inc. (NASDAQ:ZYXI ) Q3 2024 Earnings Conference Call October 24, 2024 4:15 PM ET Company Participants Quinn Callanan - IR Thomas Sandgaard - Chairman, President and CEO Dan Moorhead - CFO Donald Gregg - President, Monitoring Solutions Conference Call Participants Avi Dahan - RBC Capital Markets Jeffrey Cohen - Ladenburg Thalmann Yi Chen - H.C. Wainwright Operator Good afternoon, ladies a...
Positive
Proactive Investors
22 days ago
Zynex Inc (NASDAQ:ZYXI) announced its third-quarter 2024 financial and operational results highlighted by a 13% year-over-year increase in orders. The pain management device company reported net revenue of $50 million for the quarter ended September 30, 2024, up slightly from $49.9 million in the prior-year period.
Neutral
PRNewsWire
22 days ago
ENGLEWOOD, Colo. , Oct. 24, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the third quarter ended September 30, 2024.
More Zynex, Inc. News

Company Profile

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. Zynex was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Head office United States
CEO Thomas Sandgaard
Employees 1,100
Founded 1996
Website www.zynex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today